Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

NGNE

Neurogene Inc

Oct 11 • 04:00PM ET

49.43

Dollar change +1.28
Percentage change 2.66	%

Healthcare • Biotechnology • USA • NASD

Peers: ACAD AXSM BLUE BTAI FATE NBIX PRTA PTCT RARE RNA

| Held by: IWM VTI DWAS VXF KOMP IWO IWN VTWO IWC ITOT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.71	Insider Own	20.86%	Shs Outstand	12.82M	Perf Week	1.73%
Market Cap	642.10M	Forward P/E	-	EPS next Y	-4.49	Insider Trans	0.00%	Shs Float	10.28M	Perf Month	22.47%
Income	-55.44M	PEG	-	EPS next Q	-1.22	Inst Own	92.46%	Short Float	18.45%	Perf Quarter	7.57%
Sales	0.93M	P/S	690.43	EPS this Y	-251.04%	Inst Trans	23.68%	Short Ratio	16.72	Perf Half Y	24.51%
Book/sh	11.93	P/B	4.14	EPS next Y	-1.54%	ROA	-40.49%	Short Interest	1.90M	Perf Year	215.24%
Cash/sh	11.85	P/C	4.17	EPS next 5Y	25.10%	ROE	-47.27%	52W Range	12.49 - 53.00	Perf YTD	155.06%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-16.09%	ROI	-33.40%	52W High	-6.74%	Beta	1.49
Dividend TTM	-	Quick Ratio	12.17	Sales past 5Y	-20.00%	Gross Margin	-323.57%	52W Low	295.76%	ATR (14)	3.47
Dividend Ex-Date	-	Current Ratio	12.17	EPS Y/Y TTM	-338.79%	Oper. Margin	-8756.32%	RSI (14)	65.38	Volatility	5.64% 9.11%
Employees	91	Debt/Eq	0.09	Sales Y/Y TTM	-	Profit Margin	-5993.62%	Recom	1.14	Target Price	51.40
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	-2842.05%	Payout	-	Rel Volume	1.51	Prev Close	48.15
Sales Surprise	-	EPS Surprise	-3.85%	Sales Q/Q	-	Earnings	Aug 09 BMO	Avg Volume	113.48K	Price	49.43
SMA20	13.57%	SMA50	26.35%	SMA200	37.05%	Trades		Volume	170,982	Change	2.66%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-27-24	Initiated	BMO Capital Markets	Outperform	$65
Jun-11-24	Initiated	Robert W. Baird	Outperform	$54
Apr-29-24	Initiated	Leerink Partners	Outperform	$46
Mar-21-24	Initiated	William Blair	Outperform	$61
Jan-08-24	Initiated	H.C. Wainwright	Buy	$45
Jan-05-24	Initiated	Stifel	Buy	$31
Jan-04-24	Initiated	TD Cowen	Outperform

Aug-09-24 02:52PM	NGNE Stock Earnings: Neurogene Misses EPS for Q2 2024 (InvestorPlace)
07:30AM	Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates (Business Wire)
Aug-07-24 07:30AM	Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome (Business Wire)
Jul-02-24 07:30AM	Neurogene to Participate in BMO Genetic Medicines Summit (Business Wire) -5.32%
Jul-01-24 07:30AM	Neurogene Announces Addition to Russell 3000 Index (Business Wire) +11.62%
09:23AM	Loading…
Jun-19-24 09:23AM	Meridian Small Cap Growth Fund Trimmed Neurogene (NGNE) on Share Price Appreciation (Insider Monkey)
Jun-18-24 09:26AM	Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome (Business Wire) -24.20%
Jun-05-24 07:30AM	Neurogene to Participate in Upcoming Conferences (Business Wire)
Jun-03-24 07:30AM	Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program (Business Wire)
May-10-24 01:54PM	NGNE Stock Earnings: Neurogene Beats EPS for Q1 2024 (InvestorPlace)
07:30AM	Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates (Business Wire)
May-07-24 06:19AM	Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting (Business Wire)
Apr-22-24 04:36PM	Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting (Business Wire)
Mar-20-24 05:31AM	Neurogene Inc (NGNE) Reports Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
Mar-18-24 04:14PM	Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates (Business Wire) +20.00%
07:30AM	Loading…
Mar-04-24 07:30AM	Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial (Business Wire) +20.47%
Feb-29-24 07:30AM	Neurogene to Participate in Upcoming Investor Conferences (Business Wire)
Jan-16-24 07:00AM	Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer (Business Wire) +7.27%
Jan-05-24 07:00AM	Neurogene Announces Business Update and 2024 Outlook (Business Wire) +6.50%
Dec-19-23 07:00AM	Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million (Business Wire) +8.17%

Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in May 2007 and is headquartered in New York, NY.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NGNE

Neurogene Inc

Upgrade your FINVIZ experience